SCHEMBL29951950

SCHEMBL29951950

CCOc1ccc(B(O)O)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
ENPP2 Q13822 1/20 0.46
NQO1 P15559 1/20 0.45
HIF1A Q16665 1/20 0.45
ERN1 O75460 2/20 0.44
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44
TUBA3C P0DPH7 2/20 0.44
TUBA1B P68363 2/20 0.44
TUBA4A P68366 2/20 0.44
TUBB4B P68371 2/20 0.44
TUBB3 Q13509 2/20 0.44
TUBB2A Q13885 2/20 0.44
TUBB8 Q3ZCM7 2/20 0.44
TUBA3E Q6PEY2 2/20 0.44
TUBA1A Q71U36 2/20 0.44
TUBA1C Q9BQE3 2/20 0.44
TUBB6 Q9BUF5 2/20 0.44
TUBB2B Q9BVA1 2/20 0.44
TUBB1 Q9H4B7 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3241115 1.00 KDM4E (0.46) KDM4EENPP2NQO1HIF1AERN1
SCHEMBL29952558 0.89 KDM4E (0.53) KDM4ENQO1MAPTTSHRMAPK1
SCHEMBL3793494 0.89 KDM4E (0.53) KDM4ENQO1MAPTTSHRMAPK1
SCHEMBL24994751 0.86 CA1 (0.44) KDM4EENPP2TUBB4ATUBBTUBA3C
SCHEMBL31119100 0.85 KDM4E (0.43) KDM4ENQO1HIF1AERN1TUBB4A
SCHEMBL1918176 0.84 ENPP2 (0.44) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL24994746 0.83 KDM4E (0.44) KDM4ENQO1HIF1AMAPTTSHR
SCHEMBL203357 0.83 CA1 (0.58) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29496939 0.83 CA1 (0.58) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29956388 0.80 L3MBTL1 (0.44) KDM4ENQO1MAPTTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A KDM4E 444/4885ENPP2 548/4885NQO1 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.